Table 1: Baseline characteristics.
|
LA cSCC n = 54 |
R/M cSCC n = 105 |
Total N = 159 |
|
|
Age, median (range) |
75 (35-95) |
72 (29-95) |
74 (29-95) |
|
Sex |
|||
|
Male |
39 (72.2) |
80 (76.2) |
119 (74.8) |
|
Female |
15 (27.8) |
25 (23.8) |
40 (25.2) |
|
ECOG PS |
|||
|
0 |
22 (40.7) |
36 (34.3) |
58 (36.5) |
|
1 |
32 (59.3) |
69 (65.7) |
101 (63.5) |
|
PD-L1 statusa |
|
||
|
CPS < 1 |
5 (9.3) |
10 (9.5) |
15 (9.4) |
|
CPS ≥ 1 |
46 (85.2) |
69 (65.7) |
115 (72.3) |
|
Missing |
3 (5.6) |
26 (24.8) |
29 (18.2) |
|
Overall Cancer Stage |
|
||
|
I |
1 (1.9) |
0 (0) |
1 (0.6) |
|
II |
7 (13.0) |
4 (3.8) |
11 (6.9) |
|
III |
25 (46.3) |
15 (14.3) |
40 (25.2) |
|
IV |
21 (38.9) |
86 (81.9) |
107 (67.3) |
|
Disease Status at Baseline |
|
||
|
LA |
54 (100) |
0 (0) |
54 (34.0) |
|
Locally recurrent only |
0 (0) |
47 (44.8) |
47 (29.6) |
|
Metastatic only |
0 (0) |
25 (23.8) |
25 (15.7) |
|
Both locally recurrent and metastatic |
0 (0) |
33 (31.4) |
33 (20.8) |
CPS: Combined Positive Score; PD-L1: Programmed Death Ligand 1
Data are n (%) unless otherwise specified.
aCPS was calculated as the number of PD-L1-staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.